530 related articles for article (PubMed ID: 27641308)
21. Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance.
Lin CC; Bruinooge SS; Kirkwood MK; Olsen C; Jemal A; Bajorin D; Giordano SH; Goldstein M; Guadagnolo BA; Kosty M; Hopkins S; Yu JB; Arnone A; Hanley A; Stevens S; Hershman DL
J Clin Oncol; 2015 Oct; 33(28):3177-85. PubMed ID: 26304878
[TBL] [Abstract][Full Text] [Related]
22. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
23. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
24. Geographic Variations and the Associated Factors in Adherence to and Persistence with Adjuvant Hormonal Therapy for the Privately Insured women Aged 18-64 with Breast Cancer in Texas.
Kim J; Kim MS; Rajan SS; Du XL; Franzini L; Kim TG; Giordano SH; Morgan RO
Curr Oncol; 2023 Mar; 30(4):3800-3816. PubMed ID: 37185401
[TBL] [Abstract][Full Text] [Related]
25. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
[TBL] [Abstract][Full Text] [Related]
26. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
Farias AJ; Wu WH; Du XL
BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
[TBL] [Abstract][Full Text] [Related]
27. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
28. Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
Tan X; Camacho TF; LeBaron VT; Blackhall LJ; Balkrishnan R
Breast Cancer Res Treat; 2017 Sep; 165(2):455-465. PubMed ID: 28639031
[TBL] [Abstract][Full Text] [Related]
29. Receipt of Regular Primary Care and Early Cancer Detection in Appalachia.
Camacho F; Hwang W; Kern T; Anderson RT
J Rural Health; 2015; 31(3):269-81. PubMed ID: 25370354
[TBL] [Abstract][Full Text] [Related]
30. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
[TBL] [Abstract][Full Text] [Related]
31. Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.
Quinn EM; Fleming C; O'Sullivan MJ
Ir J Med Sci; 2016 May; 185(2):383-92. PubMed ID: 25971465
[TBL] [Abstract][Full Text] [Related]
32. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
[TBL] [Abstract][Full Text] [Related]
33. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
[TBL] [Abstract][Full Text] [Related]
34. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
[TBL] [Abstract][Full Text] [Related]
35. Racial and ethnic differences in adjuvant hormonal therapy use.
Livaudais JC; Li C; John EM; Terry MB; Daly M; Buys SS; Habel L; Thompson B; Yanez ND; Coronado GD
J Womens Health (Larchmt); 2012 Sep; 21(9):950-8. PubMed ID: 22731764
[TBL] [Abstract][Full Text] [Related]
36. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.
Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH
Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Guérin A; Hao Y; Tang D; Peeples M; Fang A; Kageleiry A; Koo V; Li N; Wu EQ
Expert Opin Pharmacother; 2016 Jun; 17(9):1189-96. PubMed ID: 27052735
[TBL] [Abstract][Full Text] [Related]
38. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
[TBL] [Abstract][Full Text] [Related]
39. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers.
Wu XC; Lund MJ; Kimmick GG; Richardson LC; Sabatino SA; Chen VW; Fleming ST; Morris CR; Huang B; Trentham-Dietz A; Lipscomb J
J Clin Oncol; 2012 Jan; 30(2):142-50. PubMed ID: 22147735
[TBL] [Abstract][Full Text] [Related]
40. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
